AVBP
ArriVent BioPharma, Inc.
13.51
+0.02 (+0.11%)
52w low 11.36
35.83 high
8.8% of range
Financial Analysis
| (USD) | Dec 22 | Dec 23 | Dec 24 | Dec 25 | Trend |
|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 36.91M | 74.59M | 94.31M | 177.53M | |
| R&D | 30.43M | 64.88M | 79.00M | 153.35M | |
| SG&A | 6.47M | 9.71M | 15.30M | 24.18M | |
| Operating Income | -36.91M | -74.59M | -94.31M | -177.53M | |
| EBITDA | -36.91M | -74.59M | -94.31M | -177.53M | |
| Pretax Income | -36.91M | -69.33M | -80.49M | -166.31M | |
| Net Income | -36.91M | -69.33M | -80.49M | -166.31M | |
| EPS Diluted | -1.15 | -2.17 | -2.56 | -4.32 | |
| Diluted Shares | 31.96M | 31.96M | 31.47M | 38.46M |
Revenue CAGR
--
Net Income CAGR
--
EPS CAGR
--
FCF CAGR
--
Revenue YoY
--